Nicholas T. Ingolia
Known for ribosome profiling, a method that reads out which messenger RNAs ribosomes are translating across a whole genome; the study in the Atlas used this approach to map mTOR-controlled translation in prostate cancer.
Professor of Biochemistry, Biophysics and Structural Biology, Department of Molecular and Cell Biology, UC Berkeley
Portrait: UC Berkeley, Department of Molecular and Cell Biology
Nicholas Ingolia is a professor in the Department of Molecular and Cell Biology at the University of California, Berkeley, where he leads the Ingolia Lab. His name is tied to ribosome profiling, a technique that lets researchers see, across all genes at once, which messenger RNAs are being turned into protein by ribosomes at a given moment.
HSI2012 is a 2012 Nature paper led by Andrew Hsieh and Davide Ruggero. Ingolia is one of the co-authors. The team used ribosome profiling to ask what oncogenic mTOR signalling changes in prostate cancer cells. They found that it does not simply speed up all protein production. It selectively boosts the translation of a specific group of messenger RNAs involved in cell proliferation, metabolism and invasion.
A class of those pro-invasion messages was shown to drive prostate cancer invasion and metastasis downstream of mTOR, and an ATP-site mTOR inhibitor, INK128, reversed this pattern with benefit in a metastasis model. For the Atlas, the paper is a key example of mTOR acting through selective translation, and ribosome profiling is the tool that made that visible.
Milestones in the Atlas
A selection, not a full bibliography: only papers that meet the Atlas inclusion criteria.
| Year | Evidence | Study |
|---|---|---|
| 2012 | M | The translational landscape of mTOR signalling steers cancer initiation and metastasis HSI2012 Co-author of the 2012 Nature study that used ribosome profiling to show how oncogenic mTOR selectively reprograms translation to drive prostate cancer invasion and metastasis. |
Co-authors in the Atlas 5
People with a profile here who share at least one study with Nicholas T. Ingolia.
ShowHide
- Andrew C. Hsieh Showed, as first author in Davide Ruggero's lab, that oncogenic mTOR drives cancer metastasis by selectively translating a specific pro-invasion mRNA program
- Davide Ruggero Showed that oncogenic mTOR signalling reprograms which mRNAs are translated, and that tumours become addicted to this through the 4E-BP–eIF4E axis. His UCSF lab found that mTOR-driven translation of a specific set of mRNAs promotes prostate cancer invasion and metastasis
- Kevan M. Shokat Co-developed the ATP-competitive 'TORKinib' mTOR inhibitors that block both mTORC1 and mTORC2, and later, with Neal Rosen's lab at Memorial Sloan Kettering, RapaLink-1, a third-generation inhibitor that overcomes mTOR resistance mutations
- Matthew R. Janes Showed, as first author in David Fruman's lab, that a dual TORC1/2 kinase inhibitor kills leukemia cells with much weaker effects on normal lymphocytes than rapamycin
- Yi Liu Drug-discovery scientist who builds selective kinase inhibitors, including the active-site mTOR inhibitor INK128
Every researcher with a profile →
Thank you. That helps us know which pages have been read by someone who knows the work.
Thank you. We will check it and correct the page.
Thank you. Your answer was counted anonymously.